CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Severe Polyserositis Induced by PCV13 Vaccine

Published: Mon, 26 Jun 2017 12:00:00 EDT
Was the severe serositis in this 75-year-old woman an auto-inflammatory response to her recent vaccination with 13-valent pneumococcal conjugate vaccine?
Journal of Medical Case Reports

Delayed Second Dose Antibiotics for Patients With Sepsis

Published: Mon, 26 Jun 2017 12:00:00 EDT
How might delays in second antibiotic administration affect outcomes among patients admitted with sepsis?
Critical Care Medicine
Displaying results 19-20 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Flagship-backed Rubius raises $120M to take off-the-shelf red blood cell cancer therapeutics into the clinic

Published: Tue, 20 Jun 2017 15:21:37 +0000
Rubius Therapeutics has raised $120 million to take two of its off-the-shelf red blood cell therapies into the clinic. The Flagship Pioneering-backed biotech is using its method for expressing proteins on allogeneic red blood cells to create candidates that hit multiple immuno-oncology targets.

Merck Ventures, CRUK launch new immuno-oncology spinout biotech iOnctura

Published: Tue, 20 Jun 2017 13:54:52 +0000
German Merck, fresh off it and partner Pfizer’s FDA approval for their checkpoint inhibitor Bavencio, and R&D charity CRUK are coming together to launch a biotech focused on immuno-oncology.

R&D costs growing, Roche shines and Novo high for ROI: It’s the EP report

Published: Tue, 20 Jun 2017 12:32:42 +0000
EvaluatePharma says spending on global pharma research will hit $181 billion in five years as Roche, AbbVie and AstraZeneca are seen as having some of the biggest potential pipeline meds.
Displaying results 19-21 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top